title: Clinical use of colony-stimulating factor-1 in ovulation induction for poor responders.
abstract: OBJECTIVE
  To evaluate the benefit of colony-stimulating factor-1 (CSF-1) adjuvant therapy to poor responders during a controlled ovarian hyperstimulation (COH) cycle.
  
  
  METHODS
  Prospective clinical study.
  
  
  METHODS
  University hospital, general hospital, and private IVF clinic in Japan.
  
  
  METHODS
  Thirty normogonadotropic patients who did not respond to conventional COH protocols.
  
  
  METHODS
  Eight million units of recombinant human CSF-1 were administered IV every other day during ovarian stimulation using FSH or hMG to 30 normogonadotropic poor responders. Serum CSF-1 concentrations were assayed on day 3. Additional studies were performed in a private IVF clinic on 27 poor responders with low serum CSF-1 levels.
  
  
  METHODS
  Pregnancy rates (PR). In addition, number of mature follicles, cycle cancellations, amount of required gonadotropins were documented.
  
  
  RESULTS
  Significantly more mature follicles, fewer cycle cancellations, and lower amounts of required gonadotropins were seen in the group treated with CSF-1. Five (16.7%) pregnancies were achieved. The CSF-1-effective patients displayed significantly lower serum CSF-1 concentrations. In a private IVF clinic, CSF-1 treatment increased the number of mature oocytes, fertilized eggs, and transferred embryos. Cycle cancellations decreased from 18.5%-3.7%; 11 pregnancies (40.7%) resulted from treatment.
  
  
  CONCLUSIONS
  Concomitant administration of CSF-1 and hMG improved follicle developments, especially in patients with low serum CSF-1 levels in the early follicular phase.
authors: Department of Obstetrics and Gynecology, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan.
authors: Akihisa
authors: A
authors: Takasaki
authors: Takashi
authors: T
authors: Ohba
authors: Yoshinori
authors: Y
authors: Okamura
authors: Ritsuo
authors: R
authors: Honda
authors: Moritoshi
authors: M
authors: Seki
authors: Nobuyuki
authors: N
authors: Tanaka
authors: Hitoshi
authors: H
authors: Okamura
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D010064:Embryo Implantation; D004624:Embryo Transfer; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D006801:Humans; D007246:Infertility / Q000378:metabolism / Q000628:therapy*; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood / Q000627:therapeutic use*; D008596:Menotropins / Q000627:therapeutic use; D054315:Oocyte Retrieval; D010062:Ovulation Induction; D010865:Pilot Projects; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005300:Fertility Agents, Female; D011994:Recombinant Proteins; D008596:Menotropins; D016173:Macrophage Colony-Stimulating Factor